Leptin activates STAT3 and ERK1/2 pathways and induces endometrial cancer cell proliferation

Abstract

Obesity is an established risk factor for endometrial cancer. Leptin, a secreted protein of the ob gene by white adipose tissue, plays an important role in the regulation of food intake and energy consumption in the brain and acts as a potential growth stimulator in normal and neoplastic cancer cells. However, a direct role for leptin in endometrial cancer has not been demonstrated. In the present study, the effect of leptin on the proliferation of Ishikawa endometrial cancer cells was investigated as well as the possible mechanism(s) underlying this action in endometrial cancers which express both short and long isoforms of leptin receptors. The expression of leptin receptor (ObRb) in Ishikawa cells was detected by RT-PCR and Western blotting. The cells after serum starvation, were treated by leptin with various concentrations (0, 10, 50, 100, 150 ng/mL) for different durations (6, 12, 24 h). The effect of leptin treatment on cell proliferation was examined by MTT assay. Meanwhile, inhibitory effect of Janus tyrosine kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) inhibitor AG490 or extracellular signal-regulated kinase 1/2 (ERK1/2) inhibitor PD98059 on the proliferation of Ishikawa cells induced by leptin was also studied. Ishikawa cells were treated with 100 ng/mL leptin for various periods (0, 20, 40, 60 min), and the levels of STAT3 phosphorylation and ERK1/2 phosphorylation were examined by Western blotting. The results showed that leptin induced the phosphorylation of STAT3 and the activation of ERK1/2 in a time- and dose-dependent manner in the Ishikawa endometrial cancer cells. Blocking STAT3 phosphorylation with the inhibitor AG490, or blocking ERK1/2 activation by the specific ERK1/2 kinase inhibitor, PD98059, abolished leptin-induced proliferation of Ishikawa cells. In addition, leptin was found to potently induce the invasion of endometrial cancer cells in a Matrigel invasion assay. Leptin-stimulated invasion was effectively blocked by pharmacological inhibitors of STAT3 (AG490) and ERK1/2 kinase (PD98059). These results suggested that leptin promotes endometrial cancer growth and invasiveness by activating STAT3 and ERK1/2 signaling pathways and therefore blocking its action at the receptor level can be a rational therapeutic strategy.

Keywords

leptin / endometrial cancer / signal transducer and activator of transcription 3 / extracellular signal-regulated kinase

References

[1] ZhangY., ProencaR., MaffeiM., et al.. Positional cloning of the mouse obese gene and its human homologue. Nature, 1994, 372(6): 425-432

[2] CaroJ.F., SinhaM.K., KolaczynskiJ.W., et al.. Leptin: the tale of an obesity gene. Diabetes, 1996, 45(12): 1455-1462

[3] FriedmanJ.M., HalaasJ.L.. Leptin and the regulation of body weight in mammals. Nature, 1998, 395(5): 763-770

[4] LonnqvistF., ArnerP., NordforsL., et al.. Overexpression of the obese (ob) gene in adipose tissue of human obese subjects. Nat Med, 1995, 1(8): 950-955

[5] BouloumieA., DrexlerH.C., LafontanM., et al.. Leptin, the product of Ob gene, promotes angiogenesis. Circ Res, 1998, 83(10): 1059-1066

[6] Sierra-HonigmannM.R., NathA.K., MurakamiC., et al.. Biological action of leptin as an angiogenicfactor. Science, 1998, 281(12): 1683-1686

[7] HuangL., LiC.. Leptin: a multifunctional hormone. Cell Res, 2000, 10(1): 81-92

[8] SomasundarP., FrankenberryK.A., SkinnerH., et al.. Prostate cancercell proliferation is influenced by leptin. J Sur Res, 2004, 118(1): 71-82

[9] SomasunderP., McFaddenD.W., HilemanS.M., et al.. Leptin is a growth factor in cancer. J Sur Res, 2004, 116(4): 337-349

[10] WhiteD.W., TartagliaL.A.. Leptin and OB-R: body weight regulation by a cytokine receptor. Cytokine Growth Factor Rev, 1996, 7(3): 303-309

[11] FeiH., OkanoH.J., LiC., et al.. Anatomic localization of alternatively spliced leptin receptors (Ob-R) in mouse brain and other tissues. Proc Natl Acad Sci USA, 1997, 94(11): 7001-7005

[12] TartagliaL.A., DembskiM., WengX., et al.. Identification and expression cloning of a leptin receptor, OB-R. Cell, 1995, 83(10): 1263-1271

[13] BanksA.S., DavisS.M., BatesS.H., et al.. Activation of downstream signals by the long form of the leptin receptor. J Biol Chem, 2000, 275(7): 14563-14572

[14] RoseP.G.. Endometrial carcinoma. N Engl J Med, 1996, 335(6): 640-649

[15] JuddH.L., ShamonkiI.M., FrumarA.M., et al.. Origin of serum estradiol in postmenopausal women. Obstet Gynecol, 1982, 59(8): 680-686

[16] DeslypereJ.P.. Obesity and cancer. Metabolism, 1995, 44(1): 24-27

[17] CarrollK.K.. Obesity as a risk factor for certain types of cancer. Lipids, 1998, 33(9): 1055-1059

[18] PetridouE., BelechriM., DessyprisN., et al.. Leptin and body mass index in relation to endometrialcancer risk. Ann Nutr & Metab, 2002, 46(2): 147-151

[19] YuanS.S., TsaiK.B., ChungY.F., et al.. Aberrant expression and possibleinvolvement of the leptin receptor in endometrial cancer. Gynecol Oncol, 2004, 92(7): 769-775

[20] KodaM., SulkowskaM., WincewiczA., et al.. Expression of leptin, leptin receptor, and hypoxia-inducible factor 1 alpha in human endometrial cancer. Ann N Y Acad Sci, 2007, 95(1): 90-98

[21] CymbalukA., Chudecka-GlazA., Rzepka-GorskaI.. Leptin levels in serum depending on body mass index in patients with endometrial hyperplasia and cancer. Eur J Obstet Gynecol Reprod Biol, 2006, 26(9): 629-640

[22] AhimaR.S., OseiS.Y.. Leptin signaling. Physi Behav, 2004, 81(3): 223-241

[23] BjorbeakC., BuchholzR.M., DavisS.M., et al.. Divergent roles of SHP-2 in ERK activation by leptin receptors. J Biol Chem, 2001, 276(5): 4747-4755

[24] DienJ., AminH.M., ChiuN., et al.. Signal transducers and activators of transcription-3 up-regulates tissue inhibitor of metalloproteinase-1 expression and decreases invasiveness of breast cancer. Am J Pathol, 2006, 169(5): 633-642

[25] SuiqingC., MinZ., LirongC.. Overexpression of phosphorylated-STAT3 correlated with the invasion and metastasis of cutaneous squamous cell arcinoma. J Dermatol, 2005, 32(4): 354-360

[26] ChooM.K., SakuraiH., KoizumiK., et al.. Stimulation of cultured colon 26 cells with TNF-alpha promotes lung metastasis through the extracellular signal-regulated kinase pathway. Cancer Lett, 2005, 230(1): 47-55

[27] LamaG., MangiolaA., AnileC., et al.. Activated ERK1/2 expression in glioblastoma multiforme and in peritumor tissue. Int J Oncol, 2007, 30(11): 1333-1342

[28] PaiR., LinC., TranT., et al.. Leptin activates STAT and ERK2 pathways and induces gastric cancer cell proliferation. Biochem Biophys Res Commun, 2005, 331(8): 984-992

[29] HuX., JunejaS.C., MaihleN.J., et al.. Leptin-A growth factor in normal and malignant breast cells and for normal mammary gland development. J Nati Cancer Inst, 2002, 94(10): 1704-1711

[30] RoseD.P., KomninouD., StephensonG.D.. Obesity, adipocytokines, and insulin resistance in breast cancer. Obes Rev, 2004, 5(2): 153-165

[31] ChoiJ.H., ParkS.H., LeungP.C., et al.. Expression of leptin receptors and potential effects of leptin on the cell growth and activation of mitogen-activated protein kinases in ovarian cancer cells. J Clinl Endocrin Metab, 2005, 90(2): 207-210

[32] BaumannH., MorellaK.K., WhiteD.W., et al.. The full-length leptin receptor has signaling capabilities of interleukin 6-type cytokine receptors. Proc Natl Acad Sci USA, 1996, 93(9): 8374-8388

[33] TanabeK., OkuyaS., TanizawaY., et al.. Leptin induces proliferation of pancreatic beta cell line MIN6 through activation of mitogen-activated protein kinase. Biochem Biophys Res Commun, 1997, 241(6): 765-768

[34] BendinelliP., MaroniP., Pecori GiraldiF., et al.. Leptin activates Stat3, Stat1 and AP-1 in mouse adipose tissue. Mol Cell Endocrinol, 2000, 168(1): 11-20

[35] ZabeauL., LavensD., PeelmanF., et al.. The ins and outs of leptin receptor activation. FEBS Lett, 2003, 546(1): 45-55

[36] BowmanT., GarciaR., TurksonJ., et al.. STATs in oncogenesis. Oncogene, 2000, 19(7): 2474-2488

[37] BarreB., AvrilS., CoqueretO.. Opposite regulation of myc and p21waf1 transcription by STAT3 proteins. J Biol Chem, 2003, 278(4): 2990-2996

[38] KiuchiN., NakajimaK., IchibaM., et al.. STAT3 is required for the gp130-mediated full activation of the c-myc gene. J Exp Med, 1999, 189(1): 63-73

[39] ShiroganeT., FukadaT., MullerJ.M., et al.. Synergistic roles for Pim-1 and c-Myc in STAT3-mediated cell cycle progression and antiapoptosis. Immunity, 1999, 11(6): 709-719

[40] Catlett-FalconeR., LandowskiT.H., et al.. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity, 1999, 10(2): 105-115

[41] GiraudS., BienvenuF., AvrilS., et al.. Functional interaction of STAT3 transcription factor with the coactivator NcoA/SRC1a. J Biol Chem, 2002, 277(8): 8004-8011